- Tags: AMD
Research
AOA report analyzes ocular risks of GLP-1RAs
Released during the 2025 Optometry’s Meeting, this comprehensive rundown dives into potential rare ophthalmic side effects associated with use—and offers clinical care recommendations.
Research
GLP-1 drug users twice as likely to develop nAMD
New research findings also report risk was 3 times as high among diabetic patients with the longest exposure to GLP-1 RAs.
Research
Air pollution exposure leading to more ocular disease cases among adults
Myopic eyes demonstrated increased risk of ocular disease with exposure to air pollution.
Research
LumiThera Valeda system extension trial data expands dry AMD vision improvements
Presented at ARVO, new findings support earlier initiation and extended vision benefits of Valeda Light Delivery System out to 4.5 years.
Pipeline
Favorable safety data supports Alkeus' oral gildeuretinol for dry AMD
Presented during ARVO 2025, the modified form of Vitamin A demonstrated a slower decline in vision-related quality of life among patients diagnosed with GA secondary to AMD.
Research
Potential connection ties AMD to higher CVD risk
Any stage of AMD linked with a 2.37-fold increased risk of cardiovascular disease.
Research
Study connects HDL levels to AMD development
Key finding: A U-shaped relationship between low and high HDL and increased risk of AMD.
Products
FDA declines Regeneron's EYLEA HD sBLA for extended dosing
Request was for additional extended dosing interval > every 16 weeks; agency makes no mention of request for new indication of macular edema following RVO.
Products
Settlement paves way for US commercialization of Eylea biosimilar
Biocon Biologic’s YESAFILI (aflibercept-jbvf) now expected to launch in H2 2026 after dismissal of Regeneron’s patent infringement lawsuits.
Research
Do you need to treat subretinal fluid in AMD?
Review outlines a proposed algorithm for evaluating subretinal fluid in nAMD patients.
Business
Opthea to cut workforce by an estimated 65%
Significant layoffs follow in wake of the company's phase 3 trial failures and subsequent termination of its wet AMD program late last month.
Pipeline
FDA accepts Outlook Therapeutics' bevacizumab BLA for wet AMD
With a PDUFA date of Aug. 27, ONS-5010 (LYTENAVA) could become the first FDA-approved bevacizumab formulation targeting this retinal disease.
Research
Chronic stress linked to increased AMD risk
Study joins a growing body of evidence that chronic stress is an important risk factor for ocular diseases.
Business
Character Biosciences raises $93M to advance genetics-based AMD therapeutics
Financing will support precision medicine candidates as part of its integrated patient data platform and AI-based analytics engine.
Pipeline
Opthea terminates wet AMD program for sozinibercept
Days after phase 3 COAST trial fails primary goal, company releases expedited ShORe trial findings on anti-VEGF trap agent.
Pipeline
Opthea fails primary goal in phase 3 wet AMD on sozinibercept
Combination therapy of sozinibercept and aflibercept 2.0 mg did not achieve a mean change in BCVA from baseline to week 52; company explains next steps.
Research
Could GLP-1 receptor agonists reduce AMD risk?
GLP-1 receptor agonists demonstrate a notable effect on the risk of non-exudative AMD.
Pipeline
Luxa Biotechnology releases FIH data on RPE cell therapy for dry AMD
Stem cell-based replacement therapy shows potential with substantial BCVA gains in worse-seeing and reversal of disease trajectory in better-seeing patients.
Pipeline
Clearside Biomedical reports phase 3 plans for SCS wet AMD therapy
Announcement follows company’s end-of-phase 2 meeting with FDA to discuss next steps for CLS-AX (axitinib injectable suspension).
Research